The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

Novo Nordisk, PayPal, and Dell Technologies are modestly priced growth stocks with a lot of potential to rise higher. Buying ...

Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as ...

Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE: NVO ), which ended in June 2025, in an interview with The ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

Weight Watchers went bankrupt in May, but now it promises it's trimmed the fat off its books and is ready to rejoin the ...

On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of ...

WW International relists on Nasdaq, pivoting to menopause care with GLP-1 drugs and coaching. Click here to read an analysis ...

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its geographic reach.

The research, published in the Canadian Medical Association Journal (CMAJ) Monday, found that 32.7 per cent of Canadians ...

An Ozempic user has revealed what they believe is a 'terrifying' side effect of upping their Ozempic dose. Falling into the category of GLP-1 medications, Ozempic is FDA-approved for type two diabetes ...

In this episode of The NBR Podcast with Simon Shepherd: Obesity. Conservatively, it's a two-billion-dollar problem. But the ...